Comparison of Drug-Eluting Stents in Acute Myocardial Infarction Patients with Chronic Kidney Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To determine which drug-eluting stents are more effective in acute myocardial infarction (MI) patients with chronic kidney disease (CKD). Methods: This study included a total of 3,566 acute MI survivors with CKD from the Korea Acute Myocardial Infarction Registry who were treated with stenting and followed up for 12 months: 1,845 patients who received sirolimus-eluting stents (SES), 1,356 who received paclitaxel-eluting stents (PES), and 365 who received zotarolimus-eluting stents (ZES). CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2 calculated by the modification of diet in renal disease method. Results: At the 12-month follow-up, patients receiving ZES demonstrated a higher incidence (14.8%) of major adverse cardiac events (MACEs) compared to those receiving SES (10.1%) and PES (12%, p = 0.019). The ZES patients also had a higher incidence (3.9%) of target lesion revascularization (TLR) compared to those receiving SES (1.5%) and PES (2.4%, p = 0.011). After adjusting for confounding factors, ZES was associated with a higher incidence of MACE and TLR than SES (adjusted hazard ratio [HR], 0.623; 95% confidence interval [CI], 0.442 to 0.879; p = 0.007; adjusted HR, 0.350; 95% CI, 0.165 to 0.743; p = 0.006, respectively), and with a higher rate of TLR than PES (adjusted HR, 0.471; 95% CI, 0.223 to 0.997; p = 0.049). Conclusions: Our findings suggest that ZES is less effective than SES and PES in terms of 12-month TLR, and has a higher incidence of MACE due to a higher TLR rate compared with SES, in acute MI patients with CKD.
Abstract
Background/Aims: To determine which drug-eluting stents are more effective in acute myocardial infarction (MI) patients with chronic kidney disease (CKD). Methods: This study included a total of 3,566 acute MI survivors with CKD from the Korea Acute Myocardial Infarction Registry who were treated with stenting and followed up for 12 months: 1,845 patients who received sirolimus-eluting stents (SES), 1,356 who received paclitaxel-eluting stents (PES), and 365 who received zotarolimus-eluting stents (ZES). CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2 calculated by the modification of diet in renal disease method. Results: At the 12-month follow-up, patients receiving ZES demonstrated a higher incidence (14.8%) of major adverse cardiac events (MACEs) compared to those receiving SES (10.1%) and PES (12%, p = 0.019). The ZES patients also had a higher incidence (3.9%) of target lesion revascularization (TLR) compared to those receiving SES (1.5%) and PES (2.4%, p = 0.011). After adjusting for confounding factors, ZES was associated with a higher incidence of MACE and TLR than SES (adjusted hazard ratio [HR], 0.623; 95% confidence interval [CI], 0.442 to 0.879; p = 0.007; adjusted HR, 0.350; 95% CI, 0.165 to 0.743; p = 0.006, respectively), and with a higher rate of TLR than PES (adjusted HR, 0.471; 95% CI, 0.223 to 0.997; p = 0.049). Conclusions: Our findings suggest that ZES is less effective than SES and PES in terms of 12-month TLR, and has a higher incidence of MACE due to a higher TLR rate compared with SES, in acute MI patients with CKD.
참고문헌 (25)
- Keeley EC, "Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials", Lancet, 361, pp.13~20 (2003)
- Newell MC, "Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction", Am J Cardiol, 97, pp.1299~1302 (2006)
- Lemos PA, "Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction", J Am Coll Cardiol, 43, pp.704~708 (2004)
- Valgimigli M, "Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial", JAMA, 293, pp.2109~2117 (2005)
- Nakazawa G, "Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study", Circulation, 118, pp.1138~1145 (2008)
- Kandzari DE, "Development and performance of the zotarolimus-eluting Endeavor coronary stent", Expert Rev Med Devices, 7, pp.449~459 (2010)
- Hamilos M, "Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses", Circ Cardiovasc Interv, 1, pp.193~200 (2008)
- Nakazawa G, "The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents", Am J Cardiol, 100(8B), pp.36M~44M (2007)
- Foley RN, "Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999", J Am Soc Nephrol, 16, pp.489~495 (2005)
- Anavekar NS, "Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction", N Engl J Med, 351, pp.1285~1295 (2004)
- Halkin A, "Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial", Am Heart J, 150, pp.1163~1170 (2005)
- 정영훈, "Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation", INTERNATIONAL JOURNAL OF CARDIOLOGY, 125(0), pp.36~40 (2008), ELSEVIER IRELAND LTD
- Ong AT, "The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry", J Am Coll Cardiol, 45, pp.1135~1141 (2005)
- Windecker S, "Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization", N Engl J Med, 353, pp.653~662 (2005)
- 조윤경, "Comparison of Sirolimus and Paclitaxel-Eluting Stents for Complex Coronary Lesions: An Intravascular Ultrasound Study", The Korean Journal of Internal Medicine, 24(4), pp.323~329 (2009), 대한내과학회
- Sim DS, "Current management of acute myocardial infarction: experience from the Korea Acute Myocardial Infarction Registry", J Cardiol, 56, pp.1~7 (2010)
- National Kidney Foundation, "K", DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, 2002, pp.39(2 Suppl 1), S1~S266
- Ellis SG, "Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Multivessel Angioplasty Prognosis Study Group", Circulation, 82, pp.1193~1202 (1990)
- TIMI Study Group, "The thrombolysis in myocardial infarction (TIMI) trial: phase I findings", N Engl J Med, 312, pp.932~936 (1985)
- Gruberg L, "Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure", Catheter Cardiovasc Interv, 55, pp.66~72 (2002)
- Lee CW, "Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction", Am J Cardiol, 104, pp.1370~1376 (2009)
- Park KW, "Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction", Int J Cardiol (2011)[DOI]
- Kang WC, "Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial", EUROINTERVENTION, 7(8), pp.936~943, EUROPA EDITION
- Camenzind E, "Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern", Circulation, 115, pp.1440~1455 (2007)
- Daemen J, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study", Lancet, 369, pp.667~678 (2007)